Merck Gets China OK for Keytruda as Monotherapy for First-Line NSCLC Treatment

Date : 10/02/2019 @ 12:39PM
Source : Dow Jones News
Stock : Merck and Co Inc (MRK)
Quote : 84.9  0.0 (0.00%) @ 10:44AM

Merck Gets China OK for Keytruda as Monotherapy for First-Line NSCLC Treatment

Merck (NYSE:MRK)
Historical Stock Chart

2 Months : From Sep 2019 to Nov 2019

Click Here for more Merck Charts.

By Colin Kellaher

 

Merck & Co. (MRK) on Wednesday said China's National Medical Products Administration approved the company's cancer drug Keytruda as monotherapy for the first-line treatment in certain patients with non-small cell lung cancer.

The Kenilworth, N.J., drug maker said the approval covers patients with locally advanced or metastatic non-small cell lung cancer whose tumors express PD-L1 as determined by a NMPA-approved test, with no EGFR or ALK genomic tumor aberrations.

Merck said Keytruda is the first anti-PD-1 therapy approved in China as both monotherapy and in combination with chemotherapy for the first-line treatment of appropriate patients with non-small cell lung cancer, the most common type of lung cancer.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

October 02, 2019 08:24 ET (12:24 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest MRK Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.